Renibus Therapeutics Inc

United States - Southlake, Texas

• 19/07/2023
• Series B
• $47,000,000

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. The Company has developed a robust portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Renibus’ first-in-class lead program, RBT-1 (SnPP / FeS), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 (tetrahydrocurmin) is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models and will be in IND enabling and clinical development in 2023. RBT-3 (FeS), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be in clinical development in 2023. RBT-9 (SnPP), a potent anti-inflammatory and antioxidant drug with anti-viral properties, is one component of RBT-1. It has been investigated in a 42-patient Phase 2 RCT in COVID pneumonia as a monotherapy in hospitalized patients. RBT-9 reduced hospital length of stay by ~70%. Additional pre-clinical work is underway in NASH progression to help inform the clinical development strategy.

Related People

Frank StonebanksCo Founder

United States - San Diego County, California

Currently Co-CEO and Board Member at Renibus Therapeutics and a Special Advisor at Wavemaker 360 Health, a health tech fund. Previously Co-Founder, General Partner at Teal Ventures. 2x company founder (Triphase LP, Zosano Pharma); 4 x CEO (Renibus, Triphase, Zosano, Cynvec); corporate VC/LP (J&J, IBM)) and private VC (NovaQuest Capital Management, Lumira Ventures); GP (Triphase LP); fund structure innovation (Triphase LP); Executive in Residence, Healthcare and Lifesciences, UCSD; Advisor; Advisor/Mentor, Milken Foundation Scholars Program

Twenty-five years of global executive operational and investment experience from sales to CEO in biotech, pharma, med tech, drug delivery & HCIT, including executive management, fund formation and deal structuring/execution, negotiating, domestic & global marketing, L&A, finance, sales, venture capital investing & senior advisory, in small start ups, mid size public companies, large Fortune 50 companies, universities, not for profits, domestic and international and the public sector.

LinkedIn https://www.linkedin.com/in/sokoboy/